Navigation Links
Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
Date:3/16/2010

SAN DIEGO, March 16 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the underwriter of its recently completed public offering of common stock has exercised in full its option to purchase an additional 1,365,000 shares of common stock to cover over-allotments.  The sale of the additional shares closed on March 16, 2010.  When taking into account the sale of the additional shares at a price to the public of $2.20 per share, the aggregate gross proceeds from both closings of the offering, before underwriting discounts and commissions and other offering expenses, were approximately $23 million.

Jefferies & Company, Inc. acted as the sole book-running manager for this offering.

Neurocrine anticipates using the net proceeds from the offering to fund its research and development efforts, and for general corporate purposes, including working capital.

The securities described above are being offered by Neurocrine pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Co
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
2. Neurocrine Biosciences to Present at the Thomas Weisel Partners Healthcare Conference
3. Neurocrine Biosciences to Present at the Bear Stearns Healthcare Conference
4. Neurocrine Biosciences to Present at the A.G. Edwards Annual Emerging Growth Conference
5. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2007 Financial Results
7. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
8. Neurocrine Biosciences Announces Conference Call and Webcast to Provide Indiplon Update
9. Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA
10. Neurocrine Announces Work Force Restructuring
11. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapeutics addressing cancer and ... a primary commercial focus on China ... Type C meeting with the U.S. Food and Drug ... in February 2015.  During this meeting the Company will ...
(Date:12/17/2014)... Dec. 17, 2014   Synageva BioPharma Corp. ... therapeutic products for rare disorders, announced today its presentation ... in San Francisco, CA. ... Executive Officer, will present on Monday, January 12, 2015, ... will be webcast live and may be accessed from ...
(Date:12/15/2014)... Israel , Dec. 15, 2014  BrainStorm ... leading developer of adult stem cell technologies for neurodegenerative ... Ltd. was awarded a grant of approximately $1.1 million ... Chief Scientist (OCS).  This is the eighth year that ... the Office of the Chief Scientist, which is part ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
Breaking Biology Technology:CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3
... -- WuXi PharmaTech (NYSE:,WX), a leading pharmaceutical, biotechnology ... operations in China and the United,States, today announced ... the Vice,President of Strategy., (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ... Dr. Yu worked at Pfizer Inc., where,she co-led ...
... Practices for Long-term Jatropha Development', the critical ... November 2007 position paper 'Sustainable Biodiesel Feedstock: ... It emphasizes the need to develop sustainability ... as a viable alternative energy source. Key ...
... BANNOCKBURN, Ill., July 10 Pinnacle Biologics, a,private, ... has entered into an agreement with pharmexx to ... in Western Europe. Terms of the,agreement were not ... Inc. stated, "We are,pleased to conclude this agreement ...
Cached Biology Technology:WuXi PharmaTech (NYSE: WX) Appoints Dr. Debra Yu as VP of Strategy 2Comprehensive Jatropha Standards Mandatory in Optimum Long-term Biofuel Efficacy 2Comprehensive Jatropha Standards Mandatory in Optimum Long-term Biofuel Efficacy 3Comprehensive Jatropha Standards Mandatory in Optimum Long-term Biofuel Efficacy 4Pinnacle Biologics Announces Agreement With pharmexx to Expand Sales Support Activities in Key European Markets 2
(Date:12/3/2014)... GLENDALE, Ariz. , Dec. 2, 2014 ... biometric hand readers, Inception Technologies is pleased to announce ... it easier for customers to collect the workforce data ... the problems that have been left by existing readers. ... to user interface, connectivity and modern technology. Older models ...
(Date:11/21/2014)... NEW YORK , Nov. 19, 2014  Earlier ... Board at New York College, and one of the ... for biosensor signals that are transmitted from Smartphones to ... there were Smartphones and has one of the earliest ... are discussing its usage in the military, child care, ...
(Date:11/21/2014)... , Nov. 20, 2014 C-Labs LLC, ... the Internet of Things (IoT), today announced the appointment ... chief operating officer. Previously a strategic advisor to the ... and operations. Mr. Traynor is based out of the ... He reports to Chris Muench , Chief Executive ...
Breaking Biology News(10 mins):Inception Technologies to Release New Biometric Reader 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... doesn,t end with the event itself. Blockage of blood flow ... With transplants scarce, half the people who live through a ... address this problem by engineering cardiac tissue to patch up ... Feiner under the supervision of Dr. Tal Dvir of ...
... September 23, 2013 It is often said that ... eliminate their attraction to the abused substance. New findings ... even long-term abstinence from cocaine does not result in ... currently trying to answer some of the ,chicken and ...
... Alliance, a nonprofit organization that focuses on local conservation and ... million award to address land use alteration as a significant ... The funding for the new program was awarded by ... (RDMA). Over 60 percent of emerging infectious diseases over ...
Cached Biology News:Putting the spring back in broken hearts 2Addiction: Can you ever really completely leave it behind? 2EcoHealth Alliance announces new award from USAID to combat disease emergence and climate change 2
... uses include large-scale colony-counting and plaque-lifting, microbial ... TM automated colony picking and gridding ... product number, created to easily match Cornings ... please order under the old Sigma-Aldrich number ...
Mouse Anti-Human Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 (KIR2DL4 Monoclonal Antibody Family: New...
BD BioCoat Laminin 150 mm Culture Dishes...
...
Biology Products: